(Q35016589)

5 August 2017

1 reference

title

Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care (English)

1 reference

5 August 2017

1 reference

Jeffrey S Ross

1

1 reference

5 August 2017

Geoffrey S Ginsburg

series ordinal

2

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

5 August 2017

language of work

1 reference

5 August 2017

volume

2

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

531-541

1 reference

STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Molecular diagnostics: a powerful new component of the healthcare value chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Progress in the prevention of breast cancer: concept to reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Using genetic variation to study human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

SNPing in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Biochip technologies in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Molecular and pathological characterization of inherited breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Familial colorectal cancer: pathology and molecular characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Pharmacogenetic screening and therapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Pharmacogenetics and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Pharmacogenetic determinants of anti-cancer drug activity and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Uncovering functionally relevant signaling pathways using microarray-based expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Gene expression profiling. Methods and clinical applications in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

An introduction to arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

DNA microarrays in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Gene expression analysis as an aid to the identification of drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Pharmacogenomics--teaching old drugs new tricks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Using mRNA expression profiling to determine anticancer drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Transcriptional profiling in cancer: the path to clinical pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

The proteasome: a new target for novel drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Discovery in toxicology: mediation by gene expression array technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

STI571 (Gleevec) as a paradigm for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Mylotarg: antibody-targeted chemotherapy comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Signal transduction in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Viral genome quantification as a tool for improving patient management: the example of HIV, HBV, HCV and CMV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Molecular diagnostics of infectious diseases: state of the technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Technical aspects of minimal residual disease detection in carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Modern molecular diagnostics and the management of haematological malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Proteomics: a technology-driven and technology-limited discovery science

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

Use of proteomic patterns in serum to identify ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.2.6.531

21 January 2018

Identifiers

DOI

10.1586/14737159.2.6.531

1 reference

5 August 2017

1 reference